10-Q: Vycor Medical Narrows Losses, Faces Going Concern Doubts

Vycor Medical reported improved revenue and reduced net losses for Q3 and the nine months ended September 30, 2025, but continues to face substantial doubt about its ability to continue as a going concern.

Summary

• Revenue for the three months ended September 30, 2025, increased by 31% to $513,792 from $390,852 in the prior year period.
• Revenue for the nine months ended September 30, 2025, increased by 28% to $1,446,523 from $1,134,098 in the prior year period.
• Vycor Medical segment revenue grew by 32% for the three months and 29% for the nine months ended September 30, 2025.
• Net income from continuing operations for the three months ended September 30, 2025, was $4,990, a significant improvement from a loss of $(59,770) in the prior year.
• Net loss from continuing operations for the nine months ended September 30, 2025, was $(7,811), a substantial reduction from a loss of $(100,266) in the prior year.
• The company reported a working capital deficiency of $(4,152,481) as of September 30, 2025, worsening from $(3,863,561) at December 31, 2024.
• Cash decreased by $41,418 during the nine months ended September 30, 2025, ending at $64,230.
• Substantial doubt exists regarding the company's ability to continue as a going concern due to accumulated losses and insufficient cash.

Sentiment

Score: 4

Explanation: While the company showed significant improvement in revenue growth and moved to positive operating income and reduced net losses, the worsening working capital deficiency, declining cash balance, and explicit 'going concern' warning, coupled with reliance on related party funding and the need for future capital raises, present substantial financial instability. The material weakness in internal controls further adds to the negative sentiment.

Positives

• Significant revenue growth for Vycor Medical segment: 32% for Q3 2025 and 29% for the nine months ended September 30, 2025.
• Achieved positive operating income of $32,085 for the three months ended September 30, 2025, compared to an operating loss of $(35,135) in the prior year.
• Reduced net loss from continuing operations to $4,990 for Q3 2025 from $(59,770) in Q3 2024.
• Reduced net loss from continuing operations to $(7,811) for the nine months ended September 30, 2025, from $(100,266) in the prior year.
• Gross profit increased by 28% for Q3 2025 and 20% for the nine months ended September 30, 2025.
• New product development is ongoing in the Vycor Medical division.

Negatives

• Working capital deficiency worsened to $(4,152,481) as of September 30, 2025, from $(3,863,561) at December 31, 2024.
• Cash balance significantly decreased to $64,230 as of September 30, 2025, from $105,648 at December 31, 2024.
• Cash used in operating activities was $(52,703) for the nine months ended September 30, 2025, a deterioration from $98,391 provided in the prior year.
• NovaVision segment revenue decreased by 2% for the nine months ended September 30, 2025.
• Overall gross margin decreased to 88% for Q3 2025 (from 90% in Q3 2024) and to 84% for the nine months ended September 30, 2025 (from 90% in the prior year), attributed to validation and shipping costs of new production and geographic sales mix.
• Accrued Preferred D Stock dividends totaled $2,919,330 as of September 30, 2025, representing a significant liability.
• The company has a material weakness in internal controls due to the lack of a functioning audit committee with independent members since April 1, 2021.

Risks

• Substantial doubt about the ability to continue as a going concern due to accumulated losses, working capital deficiency, and insufficient cash to meet needs through November 30, 2026.
• No guarantee that Fountainhead Capital Management Limited, the largest shareholder, will continue to provide working capital funding on an as-needed basis.
• Uncertainty regarding the extension of the $300,000 term note to EuroAmerican Investment Corp. (plus $556,932 accrued interest) beyond its March 31, 2026 maturity date.
• Inability to obtain additional equity or debt funding on acceptable terms or at all, which could lead to delays or curtailment of product development/commercialization or cessation of operations.
• Potential negative impact on international revenues from retaliatory tariffs imposed by countries to which the company exports, despite US-based manufacturing.
• Raw material prices may increase and supply chains could be disrupted due to global trade tariffs.
• A material weakness in internal controls exists due to the lack of a functioning audit committee with independent members, which could result in material misstatements in financial statements.

Future Outlook

The company plans to continue executing its strategy for revenue growth, focusing on increasing market penetration and international growth for Vycor Medical, and pursuing partnerships, licensing, mergers, or sales for NovaVision. It anticipates purchasing approximately $75,000 of new inventory for VBAS devices in the next twelve months and expects limited investing activities. However, the company believes it may not have sufficient cash to meet its needs through November 30, 2026, without additional debt or equity funding.

Management Comments

• The Company is executing on a plan to achieve a reduction in operating losses.
• The Company is continuing to execute on a plan to achieve revenue growth.
• Management is also open to a broad range of alternatives for NovaVision as a whole, which could comprise distribution and marketing partnerships, licensing, merger or sale.
• The Company believes it may not have sufficient cash to meet its various cash needs through November 30, 2026 unless the Company is able to obtain additional cash from the issuance of debt or equity securities.
• Management believes that the lack of a functioning audit committee and the lack of a majority of outside directors on our board of directors, results in ineffective oversight in the establishment and monitoring of required internal controls and procedures, which could result in a material misstatement in our financial statements in future periods.

Industry Context

The company operates in the medical device industry, specifically neurosurgery and non-invasive vision rehabilitation. The strategy to increase market penetration and international growth for Vycor Medical aligns with typical growth strategies for medical device companies. The exploration of partnerships, licensing, or sale for NovaVision suggests a strategic re-evaluation of its position within the digital health and non-medical areas, potentially seeking to leverage external resources for market access given its niche. The mention of European medical device regulatory transition costs in 2024 highlights the ongoing regulatory complexities and costs in the global medical device sector.

Corporate Governance

Related Party Transactions

• Fountainhead Capital Management Limited (Fountainhead), whose investment managers are Peter Zachariou and David Cantor (directors), owned 60.9% of Common Stock and 69.7% of Series D Preferred Stock as of September 30, 2025.
• Peter Zachariou owned 0.15% of Common Stock and 25.7% of Series D Preferred Stock as of September 30, 2025.
• Adrian Liddell, Chairman, is a consultant to Fountainhead.
• Accrued Preferred D Stock dividends totaled $2,919,330 as of September 30, 2025, with $2,034,332 regarding Fountainhead and $750,473 regarding Peter Zachariou.
• Accrued interest on related party loans was $37,713 for the nine months ended September 30, 2025.
• Paid accrued interest on related party loans was $15,000 for the nine months ended September 30, 2025.
• Fountainhead has provided working capital funding on an as-needed basis, but there is no guarantee this will continue.
• A $300,000 term note to EuroAmerican Investment Corp. (plus $556,932 accrued interest) is due March 31, 2026, with no assurance of further extension. EuroAmerican Investment Corp. is a related party as per the amendment agreement details.

Stakeholder Impact

• Shareholders: Potential for significant dilution if new equity is issued to address liquidity. Existing common stockholders face ongoing losses available to them due to preferred stock dividends. The 'going concern' doubt poses a fundamental risk to investment value.
• Creditors: The substantial working capital deficiency and 'going concern' doubt increase credit risk. The EuroAmerican note's maturity without guaranteed extension is a specific concern.
• Employees: Potential for delays or curtailment of operations if adequate funding is not secured, which could impact employment.
• Customers: Potential for delays or curtailment of product development or commercialization if funding is insufficient, which could affect product availability or support.
• Suppliers: Potential for payment delays or disruptions if liquidity issues persist.

Next Steps

• Seek additional equity or debt funding to address liquidity issues and going concern doubts.
• Continue executing the strategy for Vycor Medical to increase market penetration, international growth, and new product development.
• Explore partnerships, licensing, merger, or sale for the NovaVision segment.
• Address the material weakness in internal controls related to the lack of a functioning audit committee with independent members.
• Anticipate purchasing approximately $75,000 of new inventory for VBAS devices during the next twelve months.
• Evaluate the impact of new accounting pronouncements (ASU 2023-09, ASU 2024-03, ASU 2025-05) for future adoption.

Key Dates

Recommendation

Despite improvements in revenue and operating income, the company faces severe liquidity challenges, evidenced by a worsening working capital deficiency and declining cash balance. The explicit 'going concern' warning, coupled with reliance on uncertain related-party funding and the stated need for significant capital raises, indicates a high risk of financial distress or even failure. The material weakness in internal controls further undermines confidence. For a seasoned investor, these fundamental financial and governance issues outweigh the operational improvements, making the stock a strong sell due to the high probability of significant capital impairment.

Keywords

Vycor Medical, NovaVision, neurosurgery devices, vision restoration therapy, medical devices, SEC filing, 10-Q, financial results, going concern, working capital deficiency, revenue growth, operating income, stock-based compensation, related party transactions, internal controls, trade tariffs, healthcare technology